ORAL GLP RECEPTOR AGONISTS Russian patent published in 2025 - IPC A61K38/26 C07K14/605 

FIELD: chemistry.

SUBSTANCE: group of inventions relates to novel GLP-1 and/or GLP-2 receptor agonists. Disclosed is a compound containing a sequence of formula (1a) or formula (1b):

where S, T, W, Z, AA¹, AA², AA³, AA⁴, AA⁵, AA⁶, AA⁷, AA⁸, AA⁹, AA¹⁰, AA¹¹, AA¹², AA¹³, AA¹⁴, AA¹⁵, A¹⁶, AA¹⁷, AA¹⁸, AA¹⁹, AA²⁰, AA²¹, AA²², S^a, T^a, W^a, X^a, Y^a, Z^a, AA^1a, AA^2a, AA^3a, AA^4a, AA^5a, AA^6a, AA^7a, AA^8a, AA^9a, AA^10a, AA^11a, AA^12a, AA^13a, AA^14a, AA^15a, A^16a, R, R¹ and R² are defined in the patent claim, or its tautomeric or stereochemically isomeric form, or its prodrug, salt or zwitterion. Also disclosed is a pharmaceutical composition having GLP-1 and/or GLP-2 receptor agonist activity.

EFFECT: group of inventions provides treating, preventing, relieving, controlling or reducing the risk of disorders associated with glucagon-like peptide (GLP) receptors.

22 cl, 5 ex, 3 tbl